Catalent Inc.

64.27+1.63+2.60%Vol 1.38M1Y Perf -41.95%
Mar 24th, 2023 16:04 DELAYED
BID56.00 ASK77.14
Open62.41 Previous Close64.27
Pre-Market- After-Market64.76
 - -  0.49 0.76%
Target Price
81.55 
Analyst Rating
Moderate Buy 1.79
Potential %
26.89 
Finscreener Ranking
★★     45.86
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★+     54.47
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★     50.64
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
31.59 
Earnings Rating
Strong Sell
Market Cap11.57B 
Earnings Date
2nd May 2023
Alpha0.01 Standard Deviation0.10
Beta1.33 

Today's Price Range

61.0464.42

52W Range

40.69115.34

5 Year PE Ratio Range

27.80112.00

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Sell
Performance
1 Week
-4.23%
1 Month
-5.46%
3 Months
48.26%
6 Months
-15.51%
1 Year
-41.95%
3 Years
32.98%
5 Years
63.12%
10 Years
-

TickerPriceChg.Chg.%
CTLT64.271.63002.60
AAPL160.251.32000.83
GOOG106.08-0.1850-0.17
MSFT280.572.91001.05
XOM103.530.12000.12
WFC36.23-0.3800-1.04
JNJ152.651.52001.01
FB196.640.99000.51
GE91.37-0.2200-0.24
JPM124.91-1.9300-1.52
 
ProfitabilityValueIndustryS&P 500US Markets
32.60
13.10
21.30
11.30
8.92
RevenueValueIndustryS&P 500US Markets
3.61B
20.05
12.73
16.88
Earnings HistoryEstimateReportedSurprise %
Q02 20230.640.62-3.12
Q01 20230.490.25-48.98
Q04 20221.101.121.82
Q03 20220.891.0012.36
Q02 20220.790.857.59
Q01 20220.580.638.62
Q04 20211.011.086.93
Q03 20210.730.786.85
Earnings Per EndEstimateRevision %Trend
12/2022 QR0.64-15.79Negative
3/2023 QR0.85-13.27Negative
6/2023 FY2.93-17.70Negative
6/2024 FY3.33-20.53Negative
Next Report Date2nd May 2023
Estimated EPS Next Report0.64
Estimates Count7
EPS Growth Next 5 Years %4.90
Volume Overview
Volume1.38M
Shares Outstanding180.09K
Shares Float140.79M
Trades Count19.62K
Dollar Volume87.20M
Avg. Volume2.06M
Avg. Weekly Volume2.00M
Avg. Monthly Volume1.79M
Avg. Quarterly Volume2.39M

Catalent Inc. (NYSE: CTLT) stock closed at 64.27 per share at the end of the most recent trading day (a 2.6% change compared to the prior day closing price) with a volume of 1.38M shares and market capitalization of 11.57B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 17300 people. Catalent Inc. CEO is John R. Chiminski.

The one-year performance of Catalent Inc. stock is -41.95%, while year-to-date (YTD) performance is 42.79%. CTLT stock has a five-year performance of 63.12%. Its 52-week range is between 40.69 and 115.335, which gives CTLT stock a 52-week price range ratio of 31.59%

Catalent Inc. currently has a PE ratio of 20.30, a price-to-book (PB) ratio of 1.82, a price-to-sale (PS) ratio of 2.40, a price to cashflow ratio of 46.70, a PEG ratio of 2.32, a ROA of 4.45%, a ROC of 6.12% and a ROE of 10.34%. The company’s profit margin is 8.92%, its EBITDA margin is 21.30%, and its revenue ttm is $3.61 Billion , which makes it $20.05 revenue per share.

Of the last four earnings reports from Catalent Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.64 for the next earnings report. Catalent Inc.’s next earnings report date is 02nd May 2023.

The consensus rating of Wall Street analysts for Catalent Inc. is Moderate Buy (1.79), with a target price of $81.55, which is +26.89% compared to the current price. The earnings rating for Catalent Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Catalent Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Catalent Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 12.67, ATR14 : 2.99, CCI20 : -172.55, Chaikin Money Flow : -0.05, MACD : 0.04, Money Flow Index : 32.81, ROC : -7.91, RSI : 45.08, STOCH (14,3) : 29.15, STOCH RSI : 0.22, UO : 44.19, Williams %R : -70.85), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Catalent Inc. in the last 12-months were: Alessandro Maselli (Sold 816 shares of value $87 230 ), Aristippos Gennadios (Sold 806 shares of value $86 161 ), John R. Chiminski (Sold 9 691 shares of value $1 035 967 ), Jonathan Arnold (Sold 188 shares of value $20 097 ), Kay A Schmidt (Sold 323 shares of value $34 529 ), Lorenzo Carletti (Sold 631 shares of value $67 454 ), Manja Boerman (Sold 780 shares of value $40 326 ), Mario Gargiulo (Sold 2 174 shares of value $232 327 ), Michael A. Riley (Sold 2 491 shares of value $259 238 ), Michael J. Grippo (Sold 797 shares of value $85 498 ), Ricardo Pravda (Sold 427 shares of value $45 646 ), Ricky Hopson (Sold 10 000 shares of value $918 290 ), Scott Gunther (Sold 2 483 shares of value $261 098 ), Steven L. Fasman (Sold 15 092 shares of value $1 615 039 ), Thomas P. Castellano (Sold 347 shares of value $37 094 ), Thomas W. Hawkeswood (Sold 930 shares of value $72 038 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (50.00 %)
6 (50.00 %)
6 (54.55 %)
Moderate Buy
2 (16.67 %)
2 (16.67 %)
2 (18.18 %)
Hold
4 (33.33 %)
4 (33.33 %)
3 (27.27 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.79
Moderate Buy
1.79
Moderate Buy
1.68

Catalent Inc.

Catalent Inc is a specialty and generic drug manufacturing company. The company focuses on advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. The vast majority of Catalent's sales are generated in the United States, followed by Europe and the rest of the world. Most of the company's sales are derived from branded drug products. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. It operates in four operating segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services.

CEO: John R. Chiminski

Telephone: +1 732 537-6200

Address: 14 Schoolhouse Road, Somerset 08873, NJ, US

Number of employees: 17 300

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

61%39%

Bearish Bullish

53%47%

TipRanks News for CTLT

Wed, 08 Feb 2023 13:15 GMT Catalent (CTLT) Gets a Buy from Jefferies

- TipRanks. All rights reserved.

Sat, 04 Feb 2023 22:09 GMT Danaher has expressed takeover interest in Catalent, Bloomberg says

- TipRanks. All rights reserved.

News

Stocktwits